Amedisys, Inc.

NasdaqGS:AMED Stock Report

Market Cap: US$3.0b

Amedisys Past Earnings Performance

Past criteria checks 3/6

Amedisys's earnings have been declining at an average annual rate of -24%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 3.4% per year. Amedisys's return on equity is 6.9%, and it has net margins of 3.6%.

Key information

-24.0%

Earnings growth rate

-24.2%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate3.4%
Return on equity6.9%
Net Margin3.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance

Nov 05

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Apr 10
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Feb 25
Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Feb 10
Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jan 03
At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Dec 16
A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Nov 12
Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

Sep 19
Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04
An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04
Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20
We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04
At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05
Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06
Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20
Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19
Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18
These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18
Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23
Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28
Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02
It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Revenue & Expenses Breakdown

How Amedisys makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:AMED Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,321837870
30 Jun 242,290927820
31 Mar 242,251-217800
31 Dec 232,236-107800
30 Sep 232,22837740
30 Jun 232,22927690
31 Mar 232,2341127630
31 Dec 222,2231197540
30 Sep 222,2201217450
30 Jun 222,2161407360
31 Mar 222,2221917230
31 Dec 212,2142097110
30 Sep 212,2062201,0330
30 Jun 212,1962479110
31 Mar 212,1172027850
31 Dec 202,0721846680
30 Sep 202,0211662160
30 Jun 201,9721282140
31 Mar 201,9801272190
31 Dec 191,9561276080
30 Sep 191,8891272070
30 Jun 191,8121241970
31 Mar 191,7311231890
31 Dec 181,6631191850
30 Sep 181,626881810
30 Jun 181,583711780
31 Mar 181,546421780
31 Dec 171,511301770
30 Sep 171,474431810
30 Jun 171,456401870
31 Mar 171,438461900
31 Dec 161,419371960
30 Sep 161,391411980
30 Jun 161,358381930
31 Mar 161,313381880
31 Dec 151,266-31730
30 Sep 151,230-71580
30 Jun 151,204-71490
31 Mar 151,193-101420
31 Dec 141,188131470
30 Sep 141,191-41530
30 Jun 141,192-1031610
31 Mar 141,203-1091670

Quality Earnings: AMED has a large one-off loss of $60.8M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: AMED's current net profit margins (3.6%) are higher than last year (0.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AMED's earnings have declined by 24% per year over the past 5 years.

Accelerating Growth: AMED's earnings growth over the past year (3031.9%) exceeds its 5-year average (-24% per year).

Earnings vs Industry: AMED earnings growth over the past year (3031.9%) exceeded the Healthcare industry 15.5%.

Return on Equity

High ROE: AMED's Return on Equity (6.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 09:57
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Amedisys, Inc. is covered by 32 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian HoffmanAvondale Partners
Matthew GillmorBaird
Steven ValiquetteBarclays